Benefits of Valoctocogene Roxaparvovec Persist in Hemophilia A

FRIDAY, March 3, 2023 -- For patients with hemophilia A, factor VIII activity and bleeding reduction persist at two years after gene transfer with valoctocogene roxaparvovec, which delivers a B-domain-deleted factor VIII coding sequence with an...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news